BioClin Therapeutics, Inc. Announces Poster Presentation of B-701 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

(San Leandro, California, May 17, 2018) BioClin Therapeutics, Inc., a clinical stage drug development company announced today that data will be presented from its ongoing Phase 1b/2 study of B-701, a first-in-class anti-fibroblast growth factor receptor 3 (FGFR3) monoclonal antibody, plus docetaxel for metastatic bladder cancer at a poster session at the 2018 American Society for Clinical Oncology (ASCO) meeting being held June 1-5, 2018 in Chicago, IL.

The details of the poster presentation are as follows:

[Abstract 4534]
FIERCE-21: Phase 1b/2 study of Docetaxel + B-701, a Selective Inhibitor of FGFR3, in Relapsed or Refractory (R/R) Metastatic Urothelial Carcinoma (mUCC).

Joaquim Bellmunt, M.D., Ph.D., Dana-Farber Cancer Institute
Session: Genitourinary (Nonprostate) Cancer
Poster Session Date/Time:   Saturday, June 3, 2018, 8:00 – 11:30 a.m., CDT, Hall A

About BioClin Therapeutics, Inc.

BioClin Therapeutics, Inc. is a privately-held clinical stage biotechnology company developing biologics to address medical conditions in areas of high unmet need. The company is focused on FGFR3 (fibroblast growth factor receptor 3), a driver mutation in metastatic bladder cancer and potentially other cancers. The company’s lead program, B-701, is the only targeted biologic specific for FGFR3 in clinical development. BioClin has ongoing clinical studies in metastatic bladder cancer including B-701 monotherapy, and B-701 in combination with standard-of-care chemotherapy, as well as with pembrolizumab, an immune checkpoint inhibitor.

For more information, please visit BioClin’s website: www.bioclintherapeutics.com
Forward-Looking Statement:

This press release contains forward-looking statements about the business and prospects of BioClin Therapeutics, Inc., which involve risks and uncertainties, including, without limitation, statements about the timing and plans to conduct clinical trials of B-701 in mUC. These risks and uncertainties include, among others: timing of enrollment in and results of the clinical trials; safety of B-701 alone or in combination with other therapies; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning B-701. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The company’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. BioClin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:
Stephen Lau
Chief Executive Officer
info@bioclintherapeutics.com